Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

46.02 -1.22 (-2.57%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,503,387
Open 45.96
Bid (Size) 46.02 (1)
Ask (Size) 46.75 (1)
Prev. Close 47.24
Today's Range 45.75 - 46.88
52wk Range 36.91 - 58.10
Shares Outstanding 1,250,690,553
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Sanofi (SNY) Q4 2022 Earnings Call Transcript
SNY earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily

Performance

YTD
-6.07%
-6.07%
1 Month
-5.57%
-5.57%
3 Month
+5.51%
+5.51%
6 Month
-7.41%
-7.41%
1 Year
-12.27%
-12.27%

More News

Read More
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
Via Benzinga
Earnings Outlook For Sanofi
Via Benzinga
Hopeful Golden Cross Forms On Sanofi's Chart
Via Benzinga
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
Via Investor's Business Daily
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
Via Benzinga
Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics Competition
Via Benzinga
Alphabet, Apple And 3 Stocks To Watch Heading Into Friday
Via Benzinga
Fear & Greed Index Remains In 'Greed' Zone As Nasdaq Record Sharp Gains For Fourth Straight Week
Via Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
Sanofi Layoffs 2023: What to Know About the Latest SNY Job Cuts
Via InvestorPlace
Sanofi Might Pull Down Shutters For Two Vaccine Plants In India
Via Benzinga
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
Via Benzinga
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
Could This Vaccine Become Sanofi's Latest Blockbuster?
Via The Motley Fool
7 Blue-Chip Stocks to Buy as a New Bull Market Emerges
Via InvestorPlace
Mergers and Acquisitions in 2023 Off To A Strong Start
Via MarketBeat
Exposures Product Safety
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023
Via The Motley Fool
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
Via Investor's Business Daily
The Viral “Tripledemic” Opportunity
Via Talk Markets
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
Via Benzinga
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics
Via Benzinga
What This Drug News Could Mean for Sanofi Shareholders
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.